| Type: |
Conjugated Primary Antibody |
| Conjugated with: |
594, ALEXA FLUOR® |
| Host organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Protein/Peptide: |
Bcl2 modying factor |
| Specificity: |
This antibody reacts specifically with Bcl2 modifying factor |
| Modification: |
No modification has been applied to this antibody |
| Modification site: |
None |
| Clonality: |
Polyclonal Antibody |
| Clone: |
Polyclonal Antibodies |
| Concentration: |
1ug per 1ul |
| Antigen Source: |
KLH conjugated synthetic peptide derived from human Bcl2 modifying factor |
| Gene ID: |
90427 |
| Applications: |
IF(IHC-P) |
| Applications with corresponding dilutions: |
IF(IHC-P)(1:50-200) |
| Cross reactive species: |
Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens) |
| Cross Reactive Species details: |
However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species |
| Background information: |
BID, Bad, Bcl-2 modifying factor (Bmf) is a BH3-only protein that binds prosurvival Bcl-2 family members to initiate apoptosis, Bik, Bim, Binding results in a caspase cascade leading to apoptosis, Bmf is sequestered to Myosin V motors on Actin in the cytoskeleton by associating with Dynein light chain 2 (DLC2) homodimers, Bmf is widely expressed in tissues such as pancreas, Bmf then translocates to the mitochondria, Hrk, If the cell undergoes loss of attachment (anoikis), NOXA, PUMA and Bmf, The BH3 domain of Bmf facilitates binding to a hydrophobic groove on the surface of Bcl-2, The gene encoding Bmf maps to chromosome 15q14, and in hematopoietic tissues, are proapoptotic members of the Bcl-2 family, liver and kidney, the cytoskeleton is disrupted and Bmf is released from DLC2, where Bcl-2 (an anti-apoptotic family member) is sequestered, which include Blk, The BH3-only proteins |
| Purification method: |
Purified by Protein A |
| Storage: |
50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA |
| Excitation emission: |
590nm/617nm |
| Synonyms: |
BMF_HUMAN, Bcl-2-modying factor, Bcl2 modying factor, Bmf, FLJ00065, Bcl 2 modying factor |
| Also known as: |
Bcl2 modifying factor Antibody |
| Other name: |
Anti-Bcl2 modifying factor |
| Advisory: |
For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody |
| Properties: |
For facs or microscopy Alexa 1 conjugate |
| Conjugation: |
Alexa Fluor |
| Description: |
Complex subunit associated factors are involved in hybridoma growth, Eosinohils, NFKB 105 subunit for example is a polypetide gene enhancer of genes in B cells, eritroid proliferation and derived from promotor binding stimulating subunits on the DNA binding complex, transcription related growth factors and stimulating factors or repressing nuclear factors are complex subunits of proteins involved in cell differentiation, Aplha |
| Gene target: |
Bcl2 modifying factor |
| Short name: |
Fluor 594, Anti-Bcl2 modifying factor |
| Label: |
ALEXA |
| Alternative name: |
ALEXA Fluor 594, antibody to-B-cell CLL/lymphoma 2 modifying factor |